epoetin alfa
- Generic Name
- epoetin alfa
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
Phase 3
Completed
- Conditions
- CKD Anemia in Stable Dialysis Patients
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 741
- Registration Number
- NCT02273726
- Locations
- 🇵🇷
Research Center, San Juan, Puerto Rico
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Phase 4
Completed
- Conditions
- Renal Insufficiency, ChronicAnemiaRenal DialysisErythrocyte Transfusion
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 216
- Registration Number
- NCT02253654
- Locations
- 🇵🇷
Research Site, Toa Baja, Puerto Rico
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2133
- Registration Number
- NCT02174731
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
Phase 3
Completed
- Conditions
- Anemia in Incident Dialysis Patients
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 1043
- Registration Number
- NCT02052310
- Locations
- 🇧🇬
Invesigational Site, Stara Zagora, Bulgaria
🇷🇺Investigational site, St. Petersburg, Russian Federation
🇺🇸Meridian, Meridian, Idaho, United States
The Benefits of a Preoperative Anemia Management Program
Not Applicable
Terminated
- Conditions
- Anemia, Iron-Deficiency
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 51
- Registration Number
- NCT01888003
- Locations
- 🇺🇸
UAB Highlands Hospital, Birmingham, Alabama, United States
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT01737879
- Locations
- 🇺🇸
Research Site, Chesapeake, Virginia, United States
PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 28
- Registration Number
- NCT01685333
- Locations
- 🇧🇷
LAL Clinica, Valinhos, Sao Paulo, Brazil
PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 80
- Registration Number
- NCT01685359
- Locations
- 🇧🇷
LAL Clinica, Valinhos, Sao Paulo, Brazil
PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2012-08-14
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 80
- Registration Number
- NCT01664221
- Locations
- 🇧🇷
LAL Clinica, Valinhos, Sao Paulo, Brazil
PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2012-08-14
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 28
- Registration Number
- NCT01664195
- Locations
- 🇧🇷
LAL Clínica, Valinhos, São Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath